In ObSeva's latest attempt to stay afloat, the Swiss biotech offloads one of 2...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Nov 22, 2022 at 11:22: AM
via Only two months after a ruthless restructuring saw the company cut staff by 70% and focus much of its remaining resources on preterm labor treatment ebopiprant, ObsEva is now selling off that potential therapy as well.

article source
 

<



Similar threads

cafead
Upcoming events – Obseva&#039;s first fibroid foray and Newron&#039;s test in Retts
Replies
0
Views
231
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ObsEva will cut staff by 70% after FDA setback for uterine fibroids candidate linzagolix
Replies
0
Views
126
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA setback leads women’s health biotech ObsEva to give up on uterine fibroids drug
Replies
0
Views
164
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ObsEva files uterine fibroid drug in US, chasing AbbVie, Myovant
Replies
0
Views
106
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Obseva shows why red flags are worth heeding
Replies
0
Views
135
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote